MX2009000709A
(es)
|
2006-07-18 |
2009-02-04 |
Sanofi Aventis |
Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
ES2435779T3
(es)
*
|
2007-07-19 |
2013-12-23 |
Sanofi |
Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
|
GB0819097D0
(en)
*
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
KR102021728B1
(ko)
|
2009-02-05 |
2019-09-16 |
이뮤노젠 아이엔씨 |
신규한 벤조디아제핀 유도체
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
FR2949469A1
(fr)
*
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
BR112012020102A2
(pt)
|
2010-02-10 |
2016-11-29 |
Immunogen Inc |
anticorpos cd20 e usos dos mesmos.
|
AU2011239507B2
(en)
*
|
2010-04-15 |
2015-04-09 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
US8697688B2
(en)
*
|
2010-04-15 |
2014-04-15 |
Seattle Genetics Inc. |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
BR112012026801B8
(pt)
|
2010-04-15 |
2021-05-25 |
Medimmune Ltd |
conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
|
FR2963007B1
(fr)
*
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application therapeutique
|
MY183977A
(en)
|
2011-02-15 |
2021-03-17 |
Immunogen Inc |
Cytotoxic benzodiazepine derivatives
|
WO2012145112A2
(en)
|
2011-04-18 |
2012-10-26 |
Immunogen, Inc. |
Novel maytansinoid derivatives with sulfoxide linker
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
KR101860174B1
(ko)
|
2011-09-20 |
2018-05-21 |
메디뮨 리미티드 |
표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀
|
JP6170497B2
(ja)
|
2011-10-14 |
2017-07-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン
|
EP2755642B1
(en)
|
2011-10-14 |
2018-07-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
WO2013055987A1
(en)
*
|
2011-10-14 |
2013-04-18 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
CA2850264C
(en)
|
2011-10-14 |
2019-11-05 |
Spirogen Sarl |
Pyrrolobenzodiazepines
|
MX358757B
(es)
|
2011-10-14 |
2018-09-03 |
Seattle Genetics Inc |
Pirrolobenzodiazepinas y conjugados dirigidos.
|
US9676850B2
(en)
|
2012-02-24 |
2017-06-13 |
Abbvie Stemcentrx Llc |
Anti SEZ6 antibodies and methods of use
|
SG10201806867VA
(en)
|
2012-02-24 |
2018-09-27 |
Abbvie Stemcentrx Llc |
Dll3 modulators and methods of use
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
SG11201407106XA
(en)
|
2012-05-01 |
2014-11-27 |
Genentech Inc |
Anti-pmel17 antibodies and immunoconjugates
|
CA2869777C
(en)
|
2012-05-15 |
2021-11-16 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
BR112015000437A2
(pt)
|
2012-07-09 |
2017-06-27 |
Genentech Inc |
imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
|
JP2015527318A
(ja)
|
2012-07-09 |
2015-09-17 |
ジェネンテック, インコーポレイテッド |
抗cd22を含む免疫複合体
|
RU2015106673A
(ru)
|
2012-08-02 |
2016-09-20 |
Дженентек, Инк. |
Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
EP2906251B1
(en)
|
2012-10-12 |
2017-09-27 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
PT2766048E
(pt)
*
|
2012-10-12 |
2015-02-25 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
WO2014057119A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
AU2013328673B2
(en)
|
2012-10-12 |
2017-07-13 |
Medimmune Limited |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
KR20200003278A
(ko)
|
2012-10-12 |
2020-01-08 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
JP6392763B2
(ja)
|
2012-10-12 |
2018-09-19 |
エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa |
ピロロベンゾジアゼピン−抗体結合体
|
PT2906253T
(pt)
|
2012-10-12 |
2018-11-05 |
Medimmune Ltd |
Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
AU2013366490B9
(en)
|
2012-12-21 |
2018-02-01 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
EP2935268B2
(en)
|
2012-12-21 |
2021-02-17 |
MedImmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
EP2745876A1
(en)
|
2012-12-21 |
2014-06-25 |
Prous Institute for Biomedical Research, S.A. |
Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
|
CA2901114C
(en)
|
2013-02-22 |
2020-01-07 |
Stemcentrx, Inc. |
Novel antibody conjugates and uses thereof
|
AR096287A1
(es)
*
|
2013-03-13 |
2015-12-23 |
Spirogen Sàrl |
Pirrolobenzodiacepinas y conjugados
|
CN105142674B
(zh)
|
2013-03-13 |
2018-11-13 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓和其结合物
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
CN105636612B
(zh)
|
2013-08-12 |
2020-01-14 |
基因泰克公司 |
抗体-药物缀合物及使用和治疗方法
|
PE20160674A1
(es)
|
2013-08-28 |
2016-07-21 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
|
BR112016004245A2
(pt)
|
2013-08-28 |
2017-10-17 |
Stemcentrx Inc |
moduladores de sez6 e métodos de uso
|
CA2921982C
(en)
*
|
2013-09-02 |
2020-08-25 |
Hangzhou Dac Biotech Co., Ltd |
Novel cytotoxic agents for conjugation of drugs to cell binding molecule
|
KR20160055252A
(ko)
|
2013-09-17 |
2016-05-17 |
제넨테크, 인크. |
항-lgr5 항체의 사용 방법
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
DK3057585T3
(da)
|
2013-10-15 |
2020-10-19 |
Seagen Inc |
Pegylerede lægemiddel-linkere til forbedret ligandlægemiddelkonjugat-farmakokinetik
|
RU2016122041A
(ru)
|
2013-11-06 |
2017-12-11 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые анти-клаудин антитела и способы их применения
|
EP3080607A4
(en)
|
2013-12-12 |
2017-07-12 |
AbbVie Stemcentrx LLC |
Novel anti-dpep3 antibodies and methods of use
|
JP6502942B2
(ja)
|
2013-12-13 |
2019-04-17 |
ジェネンテック, インコーポレイテッド |
抗cd33抗体とイムノコンジュゲート
|
WO2015095212A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
CA3211226A1
(en)
|
2014-02-11 |
2015-08-20 |
Seagen Inc. |
Selective reduction of proteins
|
MX2016010677A
(es)
|
2014-02-21 |
2017-04-10 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
GB201407816D0
(en)
|
2014-05-02 |
2014-06-18 |
King S College London |
Pyrrolobenzodiazepine Compounds
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
EP4074735A1
(en)
|
2014-08-28 |
2022-10-19 |
BioAtla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
MA40539A
(fr)
*
|
2014-09-02 |
2016-03-10 |
Immunogen Inc |
Procédés de formulation de compositions de conjugués anticorps-médicaments
|
WO2016036804A1
(en)
|
2014-09-03 |
2016-03-10 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
WO2016036801A1
(en)
|
2014-09-03 |
2016-03-10 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
AU2015314826A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
JP7085837B2
(ja)
|
2014-09-12 |
2022-06-17 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び免疫複合体
|
MX2017003022A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados.
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
CA2959689A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
EP3197500A1
(en)
|
2014-09-17 |
2017-08-02 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
CN107148285B
(zh)
|
2014-11-25 |
2022-01-04 |
Adc治疗股份有限公司 |
吡咯并苯并二氮杂䓬-抗体缀合物
|
PE20171184A1
(es)
|
2015-01-14 |
2017-08-22 |
Bristol Myers Squibb Co |
Dimeros de benzodiazepina, conjugados de estos, y sus metodos de preparacion y uso
|
CN107231804B
(zh)
|
2015-01-14 |
2019-11-26 |
百时美施贵宝公司 |
亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
|
US9504694B2
(en)
|
2015-03-19 |
2016-11-29 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
MX2017012982A
(es)
|
2015-04-10 |
2018-07-06 |
Univ Jefferson |
Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
BR112017027258A2
(pt)
|
2015-06-23 |
2018-08-28 |
Bristol-Myers Squibb Company |
dímeros de benzodiazepina macrocíclicos, conjugados dos mesmos, preparação e usos
|
AU2015242213A1
(en)
|
2015-07-12 |
2018-03-08 |
Hangzhou Dac Biotech Co., Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
PL3325482T3
(pl)
|
2015-07-21 |
2021-01-11 |
Immunogen, Inc. |
Sposoby otrzymywania cytotoksycznych pochodnych benzodiazepiny
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
MA43835A
(fr)
|
2016-03-25 |
2018-11-28 |
Seattle Genetics Inc |
Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
|
KR20180126079A
(ko)
|
2016-04-15 |
2018-11-26 |
바이오아트라, 엘엘씨 |
항 Axl항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
|
AU2017254674A1
(en)
|
2016-04-21 |
2018-11-01 |
Abbvie Stemcentrx Llc |
Novel anti-BMPR1B antibodies and methods of use
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案
|
IL308504A
(en)
|
2016-05-13 |
2024-01-01 |
Bioatla Llc |
Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
EP3494135A1
(en)
|
2016-08-02 |
2019-06-12 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
BR112019001945A2
(pt)
|
2016-08-09 |
2019-05-07 |
Seattle Genetics, Inc. |
composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
CN116143678A
(zh)
|
2016-11-14 |
2023-05-23 |
杭州多禧生物科技有限公司 |
偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
US11697680B2
(en)
|
2016-11-21 |
2023-07-11 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
CA3045902A1
(en)
|
2016-12-21 |
2018-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
PL3544636T3
(pl)
|
2017-02-08 |
2021-12-06 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
PT3579883T
(pt)
|
2017-02-08 |
2021-09-28 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina-anticorpo
|
KR102648564B1
(ko)
|
2017-03-24 |
2024-03-19 |
씨젠 인크. |
글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
|
EP3612537B1
(en)
|
2017-04-18 |
2022-07-13 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
PL3612234T3
(pl)
|
2017-04-20 |
2024-09-02 |
Adc Therapeutics Sa |
Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek
|
US20180346488A1
(en)
|
2017-04-20 |
2018-12-06 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
AU2018268970B2
(en)
|
2017-05-19 |
2024-12-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
CA3064804A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd19 adc
|
CA3066953A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
KR102312910B1
(ko)
|
2017-08-18 |
2021-10-15 |
메디뮨 리미티드 |
피롤로벤조디아제핀 컨쥬게이트
|
US20200216463A1
(en)
|
2017-09-20 |
2020-07-09 |
Ph Pharma Co., Ltd. |
Thailanstatin analogs
|
CN117003875A
(zh)
|
2017-09-29 |
2023-11-07 |
第一三共株式会社 |
抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
|
EP3705471A4
(en)
*
|
2017-11-02 |
2021-08-11 |
UBE Industries, Ltd. |
DOUBLE-HEADED PROTEASE INHIBITOR
|
EP3710066B1
(en)
|
2017-11-14 |
2022-06-08 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
EP3732178A1
(en)
|
2017-12-28 |
2020-11-04 |
ImmunoGen, Inc. |
Benzodiazepine derivatives
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
*
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2019224340A1
(en)
|
2018-05-25 |
2019-11-28 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
AU2019301675A1
(en)
|
2018-07-12 |
2021-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
US20210308275A1
(en)
|
2018-07-31 |
2021-10-07 |
Astrazeneca Ab |
Linkers and conjugates
|
AU2019317565A1
(en)
|
2018-08-08 |
2021-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
CA3112977A1
(en)
|
2018-10-19 |
2020-04-23 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
US20210380605A1
(en)
|
2018-10-19 |
2021-12-09 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
GB201820725D0
(en)
|
2018-12-19 |
2019-01-30 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine resistance
|
EP3899048A1
(en)
|
2018-12-19 |
2021-10-27 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine resistance
|
JP2022513482A
(ja)
|
2018-12-21 |
2022-02-08 |
アビディティー バイオサイエンシーズ,インク. |
抗トランスフェリン受容体抗体およびその使用
|
WO2020141923A2
(ko)
*
|
2019-01-03 |
2020-07-09 |
주식회사 레고켐 바이오사이언스 |
안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
|
WO2020146182A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
CA3125033A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
CA3127113A1
(en)
|
2019-01-30 |
2020-08-06 |
Dongxu Sun |
Anti-gal3 antibodies and uses thereof
|
ES2967878T3
(es)
|
2019-03-15 |
2024-05-06 |
Medimmune Ltd |
Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
|
CA3133757A1
(en)
|
2019-03-29 |
2020-10-08 |
Medimmune Limited |
Compounds and conjugates thereof
|
US20230094471A1
(en)
|
2019-03-29 |
2023-03-30 |
Immunogen, Inc. |
Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CN110483504B
(zh)
*
|
2019-08-02 |
2022-04-26 |
桂林理工大学 |
以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
|
US20240124938A1
(en)
*
|
2019-10-16 |
2024-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Visual detection of pbd induced dna crosslinks
|
AU2020370125A1
(en)
|
2019-10-22 |
2022-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
|
WO2021080608A1
(en)
|
2019-10-25 |
2021-04-29 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
JP2023506158A
(ja)
|
2019-12-12 |
2023-02-15 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Cd276に特異的な抗体-薬物コンジュゲートおよびその使用
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
AU2021210570A1
(en)
|
2020-01-22 |
2022-09-01 |
Medimmune Limited |
Compounds and conjugates thereof
|
JP2023537798A
(ja)
|
2020-03-19 |
2023-09-06 |
アビディティー バイオサイエンシーズ,インク. |
顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
|
TW202202173A
(zh)
|
2020-03-27 |
2022-01-16 |
美商亞維代堤生物科學公司 |
治療肌肉萎縮症之組合物及方法
|
BR112022020332A2
(pt)
|
2020-04-10 |
2022-12-13 |
Seagen Inc |
Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
CA3213625A1
(en)
|
2021-03-18 |
2022-09-22 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
CA3213636A1
(en)
|
2021-03-18 |
2022-09-22 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
GB202105187D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB202105186D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
US20240270851A1
(en)
|
2021-06-09 |
2024-08-15 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
WO2023288252A1
(en)
|
2021-07-13 |
2023-01-19 |
Truebinding, Inc. |
Methods of preventing protein aggregation
|
GB202110726D0
(en)
|
2021-07-26 |
2021-09-08 |
Cambridge Entpr Ltd |
Conjugating reagents and conjugates thereof
|
CA3231330A1
(en)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|
GB202207691D0
(en)
|
2022-05-25 |
2022-07-06 |
Cambridge Entpr Ltd |
Quinone protected forms and conjugates
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|